|
| Study | Design, sample size, and study duration | NSAID | Treatment arms | Results | Author conclusions |
|
| Russo et al. (2013) [7] | Randomized, prospective, controlled,
56 eyes
6 months | Ketorolac 0.45% TID | Ketorolac plus IVR versus IVR alone for new exudative AMD | 37.1 µm greater CMT reduction at 6 months in ketorolac arm. No differences for VA or no. of injections | Topical ketorolac supplements the activity of intravitreal ranibizumab in reducing CMT in CNV |
| Gomi et al. (2012) [5] | Randomized, prospective, placebo-controlled,
30 eyes
6 months | Bromfenac 0.1% BID | Bromfenac plus IVR versus IVR alone for exudative AMD | Reduced CMT and fewer injections in bromfenac group, but similar VA | Bromfenac may reduce the frequency of IVR over
6 months in eyes with small CNV |
| Flaxel et al. (2012) [4] | Randomized, prospective, controlled,
30 eyes
12 months | Bromfenac 0.09% BID | Bromfenac plus IVR versus IVR alone for exudative AMD | 63.3 µm greater CMT reduction at 12 months in bromfenac arm. No differences for VA or no. of injections | Combination
is efficacious for the treatment of exudative AMD |
| Chen et al. (2010) [32] | Retrospective, uncontrolled
25 eyes
3 months | Nepafenac 0.1% TID | Nepafenac plus IVR/IVB for recalcitrant exudative AMD | No changes in VA or CMT | No significant changes in VA or CMR, but a mild trend towards improved anatomy |
| Zweifel et al. (2009) [33] | Retrospective, uncontrolled
22 eyes
2 months | Bromfenac 0.09% BID | Bromfenac plus IVR/IVB for persistent exudative AMD | No changes in VA or CMT | No beneficial effect of adding bromfenac for persistent exudative AMD |
|
